MOLECULAR EXPRESS, INC.
Biotech · Private
Synthetic lung surfactant (ME-1001) comprising Super Mini-B peptide and natural lipids for neonatal respiratory distress syndrome
- Grants
- $9.8M
- 20 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 12
- 2 granted · 10 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Design and Engineering of Nanoparticulate Universal Vaccines | $290,263 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Vaccine for the Prevention of Pulmonary Aspergillosis | $329,911 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Gene and Oligonucleotide Delivery System | $322,946 | |
| Federal grant | Department of Health and Human Services · Phase II · Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction | $225,033 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimization of VesiVax® Lipidated Tucaresol Formulations | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · The VesiVax® System: Vaccine Development Made Easy | $762,253 | |
| Federal grant | Department of Health and Human Services · Phase II · Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction | $95,143 | |
| Federal grant | Department of Health and Human Services · Phase I · VesiVax® Peanut Allergy Immunotherapy | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Vaccine for the Prevention of Pulmonary Aspergillosis | $934,456 | |
| Federal grant | Department of Health and Human Services · Phase II · The VesiVax® System: Vaccine Development Made Easy | $736,747 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Vaccine for the Prevention of Pulmonary Aspergillosis | $497,338 | |
| Federal grant | Department of Health and Human Services · Phase II · Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS | $956,889 | |
| Federal grant | Department of Health and Human Services · Phase I · VesiVax Vaccine Formulation Against Neisseria gonorrhoeae | $299,817 | |
| Federal grant | Department of Health and Human Services · Phase II · Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS | $1,031,789 | |
| Federal grant | Department of Health and Human Services · Phase I · Niclosamide Formulations for the Treatment of Influenza Infections | $298,479 | |
| Federal grant | Department of Health and Human Services · Phase II · Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS | $67,200 | |
| Federal grant | Department of Health and Human Services · Phase II · Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS | $113,400 | |
| Federal grant | Department of Health and Human Services · Phase I · VesiVax Vaccine Formulation Against Neisseria gonorrhoeae | $299,779 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Development of a ME-1001, a Synthetic Lung Surfactant | $999,853 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Development of a ME-1001, a Synthetic Lung Surfactant | $999,784 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1925 | Arch Innotek, LLC | — | — |
| 1926 | GENELANCET BIOSCIENCES INC | — | — |
| 1927 | CODA Biotherapeutics, Inc. | — | — |
| 1928 | MOLECULAR EXPRESS, INC. | — | — |
| 1929 | Surf Air Global Ltd | — | $9.9M |
| 1930 | GENOMEDESIGNS LABORATORY, LLC | — | — |
| 1931 | Prologue Medicines | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Methods And Compositions For Substance Use Disorder Vaccine Formulations And Uses Thereofgranted
- Methods And Compositions For Substance Use Disorder Vaccine Formulations And Uses Thereofapplication
- Methods And Compositions For Liposomal Formulation Of Antigens And Uses Thereofgranted
- Foam Patent Surfactantapplication
- Foam Patent Surfactantapplication
- Light Activated Nanoparticle Compositions And Uses Thereofapplication
- Methods And Compositions For Substance Use Disorder Vaccine Formulations And Uses Thereofapplication
- Nanoparticle Formulations Of Poorly Soluble Compoundsapplication
- Surfactant Preparations For Pulmonary Delivery, And Methods For The Preparation And Use Thereofapplication
- Liposomal Formulationsapplication
- Surfactant Preparations For Pulmonary Delivery, And Methods For The Preparation And Use Thereofapplication
- Light Activated Nanoparticle Compositions And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.